bs-16222R **[Primary Antibody]**

GALNT6 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 11226 **SWISS:** Q8NCL4

Target: GALNT6

Immunogen: KLH conjugated synthetic peptide derived from human GALNT6: 351-450/622.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a member of the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes. GalNAc-Ts initiate mucin-type O-linked glycosylation in the Golgi apparatus by catalyzing the transfer of GalNAc to serine and threonine residues on target proteins. They are characterized by an N-terminal transmembrane domain, a stem region, a lumenal catalytic domain containing a GT1 motif and Gal/GalNAc transferase motif, and a C-terminal ricin/lectin-like domain. GalNAc-Ts have different, but overlapping, substrate specificities and patterns of expression. The encoded protein is capable of glycosylating fibronectin peptide in vitro and is expressed in a fibroblast cell line, indicating that it may be involved in the synthesis of oncofetal fibronectin. [provided by RefSeq, Jul 2008]

Applications: **WB** (1:500-2000)

Reactivity: Mouse (predicted: Human, Rat, Rabbit)

Predicted MW.: 71 kDa

Subcellular Location: Cytoplasm

VALIDATION IMAGES



Sample: intestine (mouse) Lysate at 40 ug placenta (mouse) Lysate at 40 ug Primary: Anti-GALNT6 (bs-16222R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 71 kD Observed band size: 71 kD

SELECTED CITATIONS

- **[IF=4.5]** Luhaoran Sun. et al. N-acetylgalactosaminyltransferase GALNT6 is a potential therapeutic target of clear cell renal cell carcinoma progression. CANCER SCI. 2024 Aug;: IHC ;Mouse. 39105355
- **[IF=4.6]** Ziyuan Tong. et al. GALNT6, transcriptionally inhibited by KLF9, promotes osteosarcoma progression by increasing EFEMP1 expression via O-glycosylation modification. BBA-MOL CELL RES. 2024 Nov;:119879 IHC ;Mouse. 39581475